The molecule is the same everywhere. The patent is not.
In several countries the semaglutide patent has now lapsed, generic manufacturers have entered, and the price has done what prices do when a monopoly ends. In the United States the patent estate runs materially longer.
Why the gap exists
Two systems, doing exactly what they were designed to do.
Patent terms differ between jurisdictions, and manufacturers file, extend and defend them country by country. Separately, most wealthy countries negotiate as a single national purchaser, while the United States mostly does not — which is why American prices for these drugs have been several times higher throughout, generic or not.
Nothing about the chemistry changes at the border. What changes is who is allowed to make it and who is doing the negotiating.
What this means in practice for Americans
Very little that is legal, and a good deal that is risky.
Personal importation is generally not permitted. There is limited enforcement discretion in specific circumstances, but a foreign generic is not an FDA-approved product in the US and this is not a route the agency endorses.
“Canadian pharmacy” websites are frequently neither. A large share of sites presenting themselves as Canadian pharmacies are not located in Canada, not licensed anywhere, and not shipping what they claim.
Medical tourism carries a continuity problem. Buying a supply abroad while travelling is a different situation from a mail order, but it still leaves you managing a chronic medication with no local prescriber, no refills, and no recall pathway.
The compounding comparison
This development quietly weakens one of the arguments made for the gray market.
Compounded product was defended, reasonably, as the only affordable option for excluded patients. As manufacturers’ direct cash prices have fallen in response to competition, and as generics demonstrate what these drugs cost to make in a competitive market, the picture becomes less about necessity and more about a pricing structure that has now been visibly exposed.
That does not make compounded product safer. It does make the “there is no alternative” argument weaker than it was two years ago, and it is worth re-running your own arithmetic rather than assuming the position you settled on in 2024 still holds.
If you do change source — between compounded and branded, between a cash channel and a covered prescription, between products — record the date you switched and what you switched to. Sourcing changes are the most under-documented events in this whole market, and they are exactly what a clinician needs when side effects or effectiveness shift and nobody can say what else changed that month. Zenday keeps that alongside the dose history.
What to watch
Whether US patent litigation moves the timeline. Whether the direct cash channels keep falling as generic pressure builds elsewhere. And whether any of this changes the negotiating posture that produced the gap in the first place.
The honest summary: the drugs will eventually be cheap in America, as every drug eventually is. The question that matters to anyone reading this now is what happens in the years before then, and how many people spend them untreated.